Medical Oncologist
Understanding your treatment
Pazopanib Outcomes: — An Honest Look at the Numbers
There is no single success rate for pazopanib. How well it works depends on the cancer type, the stage, and factors specific to you. Understanding what the numbers actually mean — and how to ask about them — gives you a clearer picture than any headline figure.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- No single success rate — Outcomes differ significantly between kidney cancer and soft tissue sarcoma, and within each cancer type by stage and prior treatment.
- What the median means — A median figure tells you what happened in the middle of a large trial. Half the people did better than that figure; half did worse. It does not predict your outcome.
- Response is not just shrinkage — Stable disease — where the cancer stops growing — counts as a meaningful outcome on pazopanib, not only tumour shrinkage.
- Ask the right questions — The numbers that matter are the ones your oncologist can give you for your specific cancer type, stage, and treatment line.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Pazopanib does not have a single success rate. How well it works depends on the cancer type being treated, the stage, and individual factors such as prior treatment and kidney function. Published trial data shows it slows disease progression in a proportion of patients with kidney cancer and soft tissue sarcoma, but outcomes vary between individuals and between cancer types.
What does 'success rate' actually mean for a cancer drug?
A drug's success rate is not a single fixed number, and for pazopanib it depends heavily on which cancer is being treated and how outcome is measured.
Researchers track several different things: whether the tumour shrank, how long before the disease progressed, and how long patients lived overall. These produce three different figures, and none of them is the success rate.
Response rate covers only patients whose tumours shrank by a defined amount. Progression-free survival captures how long the disease stayed stable or better. Overall survival measures how long patients lived in total, which is harder to attribute to a single drug because treatment changes over time.
When your oncologist explains what pazopanib is expected to achieve for you, ask which of these measures they are referring to.
Does pazopanib work the same way for kidney cancer and soft tissue sarcoma?
No. Pazopanib is approved for two different cancer types, and the published evidence for each is different.
In advanced kidney cancer, pazopanib is one of several established options. NCCN and ASCO guidelines for kidney cancer include pazopanib as a recommended agent, based on trial data showing it delayed disease progression compared to placebo and performed comparably to other targeted agents in head-to-head studies.
In soft tissue sarcoma, the PALETTE trial compared pazopanib to placebo in patients whose disease had progressed on prior chemotherapy. ESMO guidelines for soft tissue sarcoma include pazopanib on the basis of that evidence.
The trial results are different for each cancer type. Ask your oncologist which body of evidence applies to your diagnosis and what it showed for patients in a situation similar to yours.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How do I make sense of the outcome numbers at my next appointment?
Name your starting point
Ask specifically: 'What does the trial data show for my cancer type, stage, and line of treatment?' This grounds the conversation in your situation rather than general population statistics.
Ask for the median and the range
Median progression-free survival is the most commonly cited measure for pazopanib. Ask what the published median was for patients like you, and whether the trial also reported a range — some people did much better than the median, some worse.
Ask what counts as a response
Stable disease — where the cancer stops growing — is a meaningful outcome on pazopanib, not just tumour shrinkage. Ask your team what they will be looking for on your first scan, and when that scan is planned.
Ask what the figure is being compared to
Most trial figures for pazopanib compare it to placebo or to another active treatment. A figure means something different depending on what it is measured against. Ask your oncologist to name the comparator.
Ask what the plan is if it stops working
Knowing there is a next step makes the statistics feel less final. Ask what options remain if pazopanib does not control the disease, or stops working over time.
What does a median figure actually mean — and what does it not mean?
A median is the midpoint of a group. If a trial reports a median progression-free survival of several months, it means half the people in that trial had their disease controlled for longer than that figure, and half for less.
The median describes the group. It does not tell you where in that group you will fall. Some people do far better than the median; some do worse. Your individual outcome depends on factors the trial cannot capture for you specifically.
This is not a reason to ignore the median — it is genuinely useful information about what the drug has done in people with your cancer. But treat it as a starting point for a conversation, not as a personal prediction.
If a figure worries you, say so directly. Your oncologist can explain which factors in your case — your performance status, kidney function, and prior treatments — move your likely experience closer to or further from the group average.
What do the terms my oncologist uses actually mean?
- Median
- The middle value in a set of results. Half the people in a trial did better than the median; half did worse. It is a description of a group, not a prediction for any individual.
- Progression-free survival (PFS)
- How long a patient lived without their cancer growing or spreading, measured from the start of treatment. A longer PFS means the drug kept the disease stable or better for more time.
- Overall survival (OS)
- How long patients lived in total from the start of treatment. It is harder to attribute to a single drug, because most patients receive other treatments after the study drug stops working.
- Response rate
- The proportion of patients whose tumours shrank by a defined amount. Stable disease is not counted in this figure, so a low response rate does not mean the drug is not helping — some patients benefit through stability rather than shrinkage.
- Stable disease
- When the tumour neither shrinks nor grows significantly during treatment. For a targeted therapy like pazopanib, stable disease is a meaningful outcome — it means the cancer is being held in check.
- Line of treatment
- Which treatment this is in your sequence — first-line means no prior treatment for this cancer, second-line means one prior treatment has already been tried. Trial data is collected from a specific line, and the results may not apply equally across all lines.
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is pazopanib more likely to work for kidney cancer or soft tissue sarcoma?
The evidence base is different for each. For advanced kidney cancer, pazopanib is one of several established first-line options with a substantial body of trial data behind it. For soft tissue sarcoma, it is used mainly after other treatments have been tried, and the benefit is typically measured in months of disease control rather than tumour shrinkage. Your oncologist can tell you which body of evidence applies to your diagnosis and what it showed for patients in a situation similar to yours.
What does a response rate mean when my oncologist discusses pazopanib outcomes?
A response rate tells you what proportion of patients in the relevant trial had their tumours shrink by a defined amount. It does not count patients whose disease stayed stable — and stable disease is also a meaningful benefit from pazopanib. So a response rate gives you a partial picture, not the full one. Ask your oncologist what the response rate was for your cancer type and line of treatment, and whether stable disease outcomes are separately reported.
Does pazopanib extend life?
The primary evidence for pazopanib in both kidney cancer and soft tissue sarcoma is based on progression-free survival — how long the disease stayed controlled — rather than on overall survival directly. This is partly because patients in these trials often went on to receive other treatments after pazopanib, which makes it hard to separate any single drug's contribution to overall survival. NCCN and ASCO guidelines include pazopanib because the progression-free survival data is meaningful, not because the overall survival picture is simple. Ask your oncologist how they weigh this evidence for your specific situation.
How will my oncologist know if pazopanib is working for me?
Usually by imaging — a CT scan or PET-CT — done after a defined number of weeks or months on treatment. Your team will compare the size and extent of the cancer to your baseline scans from before you started. They will also consider how you are feeling and whether any blood markers are changing. Ask when your first response assessment is planned so you are not waiting without a timeline.
What happens if pazopanib stops working?
Most oncologists plan ahead for this. In kidney cancer, there are several other targeted agents and immunotherapy combinations used after pazopanib. In soft tissue sarcoma, options after pazopanib depend on which treatments have already been tried and on the specific subtype of sarcoma. Being on pazopanib does not use up all other options. Ask your oncologist what the next step would be if the scan shows the disease has progressed, so that possibility feels planned rather than sudden.
I have read about people staying on pazopanib for several years. Is that realistic?
Some patients do respond for significantly longer than the median — that is precisely what a median means. It is not a ceiling, and some people in the trials that established pazopanib's role remained on treatment for much longer than the midpoint figure. Whether that is realistic for you depends on factors your oncologist can speak to, including how your cancer behaves on treatment and whether side effects remain manageable. Long responses do happen; they are not the experience of the majority, but they are not unusual either.